Qualigen Therapeutics, Inc. Announces management changes.
26. September 2024 17:10 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors...
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
10. April 2024 08:00 ET
|
Qualigen Therapeutics, Inc.
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN)...
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
15. August 2023 08:30 ET
|
Qualigen Therapeutics, Inc.
Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash...
Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
07. Dezember 2022 09:10 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen Therapeutics to Present at BIO International Convention
14. Juni 2022 09:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Promotes Amy Broidrick to President
14. Dezember 2021 09:18 ET
|
Qualigen Therapeutics, Inc.
Ms. Broidrick to retain title of Chief Strategy Officer CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on...
Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
14. Juli 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...